Boston Scientific closes Neovasc transaction

• Boston Scientific (NYSE:BSX) finalizes its acquisition of certain manufacturing assets and capabilities of Neovasc's (NVCN) advanced biological tissue business along with an equity investment for a total of $75M in cash.
• Previously: Neovasc up 95% premarket on Boston Scientific investment (Dec. 2)